GSK to own 80pc of GSK Nigeria
GSK could soon hold an 80 per cent stake in GSK Nigeria.
GlaxoSmithKline (GSK) and GSK Nigeria have announced an agreement in principle for the pharmaceutical giant to increase its ownership in GSK Nigeria.
If completed, the transaction would see GSK increase its stake in GSK Nigeria from 46.4 per cent to 80 per cent.
David Redfern, GSK's chief strategy officer, said the proposal "reiterates our long-term support of the company's strategy and our confidence in the continuing growth prospects of the business".
GSK Nigeria manufactures, markets and distributes a range of brands, such as Panadol and Sensodyne, as well as pharmaceutical products and vaccines, which account for approximately 30 per cent of revenue.
GSK intends to acquire around 321 million shares at an offer price of NGN 48 per share, representing a premium of 28 per cent on top of GSK Nigeria's closing share price on November 23rd 2012.
Chief Olusegun Osunkeye, chairman of GSK Nigeria, commented: "The board of directors unanimously believes that the proposal is in the best interests of the continued growth of the company, the shareholders, employees and customers, the community and Nigeria and intends to recommend it to shareholders."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance